Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has announced it will present at the Centurion One Capital 4th Annual Bahamas Summit in Nassau from October 19 to October 21, 2026. The Calgary-based autologous stem cell therapy company plans to discuss commercialisation of its investigational therapy VesCell™ in The Bahamas, supported by clinical evidence from 498 treatments, seven studies, and 11 peer-reviewed publications. The appearance at the invitation-only institutional investor event may draw attention to the company's regulatory application progress in The Bahamas.

Key Points

  • Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) is a Calgary-based autologous stem cell therapy platform company
  • Hemostemix will present at the Centurion One Capital 4th Annual Bahamas Summit, October 19–21, 2026, at Rosewood Baha Mar in Nassau
  • The company has applied under The Bahamas' Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I basket clinical trial of VesCell™
  • Investors may be watching for updates on the LARTA application outcome and Bahamian commercialisation progress

Hemostemix's Invitation to Nassau Investor Summit

The Centurion One Capital summit is an invitation-only event that brings together company executives, institutional investors, and family offices for presentations, panel discussions, and one-on-one meetings. Hemostemix intends to use the forum to introduce investors to the hospital and physicians partnering with the company in The Bahamas. President and CEO Thomas Smeenk stated the event provides an opportunity to connect the company's business to patient outcomes and the facilities where VesCell™ treatments are offered. The immediate share price impact was not clear from available public information.

LARTA Application and Bahamian Phase I Trial

Hemostemix has applied under The Bahamas' Longevity and Regenerative Therapies Act (LARTA) for its first treatment protocol — a commercial Phase I basket clinical trial evaluating VesCell™ (ACP-01) across three indications: angina, vascular dementia, and pain. The company describes this application as the first of many intended treatment protocols. No timeline for regulatory approval of the application was disclosed in the announcement, and no financing details associated with the Bahamian programme were provided.

VesCell™ Clinical Evidence Underpinning the Commercialisation Case

The company's commercialisation pitch rests on a clinical dataset spanning 498 treatments, seven studies, and 11 peer-reviewed publications. The announcement also highlights cardiac data showing ejection fraction improvement from 13.2% to 20% in one treated patient — a relative 51% improvement — alongside MRI evidence of reduced scarring and increased viable heart muscle, which the company describes as consistent with favourable reverse remodelling and improved contractility. These figures are drawn from existing clinical research cited in the release and are not forward-looking guidance.